Amfonelic Acid

Amfonelic acid is chiefly of interest as a research tool rather than as a consumer nootropic. Because it selectively elevates synaptic dopamine through transporter blockade, investigators have used it to dissect the relative contributions of the dopamine transporter and vesicular monoamine transporter 2 (VMAT2) to striatal dopamine signaling; in VMAT2-deficient mice its effect on evoked dopamine release is markedly diminished, illustrating its dependence on intact vesicular stores ^[1]. Other work has employed amfonelic acid to drive dopamine synthesis and study how tyrosine supply constrains dopamine production in the striatum ^[2].

Reports in the pharmacology literature describe amfonelic acid as considerably more potent than methylphenidate as a dopamine uptake inhibitor and note a comparatively long duration of action, which contributes to its reputation as a durable stimulant. It fully substitutes for dextroamphetamine in drug-discrimination assays despite acting through a distinct mechanism ^[3]. Because it is unapproved and long-acting with strong dopaminergic drive, its human safety profile is essentially uncharacterized in the modern literature.

Amfonelic acid is an unapproved research chemical with no established human safety data. As a potent, selective and comparatively long-acting dopamine reuptake inhibitor, it carries the general risks associated with strong dopaminergic stimulants, which can include insomnia, appetite suppression, elevated heart rate and blood pressure, anxiety or agitation, and potential for dependence with repeated use. Its long duration may prolong these effects. It is sold for laboratory research only and is not intended for human consumption.

Amfonelic acid emerged from mid-twentieth-century medicinal chemistry work on the 1,8-naphthyridine and quinolone antibacterial series associated with nalidixic acid, when certain analogues were found to possess unexpected central stimulant activity. Assigned the code WIN 25978, it was characterized as a non-amphetamine dopaminergic stimulant and subsequently became a widely cited pharmacological tool for studying dopamine transporter function.

Within neuropharmacology, amfonelic acid is respected as a clean, selective dopamine reuptake inhibitor and a useful experimental probe. In the grey-market nootropic and research-chemical community it has a reputation as an unusually potent and long-lasting stimulant, which also makes it a compound approached with caution; it has never been an approved therapeutic and human data are scarce.